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The structural features of the asymmetric activated
states of the insulin receptor family are still poorly
understood. We investigated hydrogen/deuterium
(H/D)-exchange within the extracellular domain of
the type-I insulin-like growth factor receptor (IGF-1R)
in the absence and presence of IGF-1 (active state)
and in the presence of antibody inhibitors (inactive
state). Near complete coverage of the 210 kDa
receptor sequence was obtained by mass mapping
ofproteolyticallyderivedpeptidesatallH/D-exchange
timepoints. Thedataprovidedetails regardingsolvent
exposure and dynamics across the extracellular
region as well as conformational changes induced by
activation or inactivation. Multiple peptides, distant
in structure, individually demonstrated two distinct
H/D-exchange rates, suggesting that each of these
peptides exists in two separate environments in
IGF-1R. The dual-exchange behavior of these pep-
tides was enhanced on ligand binding and eliminated
on inhibitor binding, clearly associating these regions
with active state asymmetry and enabling them to
serve as reporters of receptor activity.
INTRODUCTION
The type-I insulin-like growth factor receptor (IGF-1R) is
a member of the insulin-receptor family of receptor tyrosine
kinases. It plays essential roles in fetal and adolescent growth
and development and in metabolism as part of its ancestral rela-
tionship to the insulin receptor (IR) (Clemmons, 2007). Insulin is
the primary ligand for IR, and IGF-1 and IGF-2 are the ligands
for IGF-1R. The ligands are structurally related to one another
as are IGF-1R and IR (De Meyts and Whittaker, 2002). The
mature form of IGF-1R, on the cell surface, is a homodimer of
two independently synthesized polypeptide chains that are
each cleaved in their extracellular domains by furin to produce
a heterotetramer consisting of two N-terminal a- and two
C-terminal b-chains (Adams et al., 2000). Each half of the heter-890 Structure 19, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rightsotetrameric receptor (a- and b-chains) contains six extracellular
domains consisting (fromN toC terminus) of a receptor L domain
(L1), a cysteine-rich region (CRR), another receptor L domain
(L2), and 3 Type-III fibronectin domains (FnIII-1, FnIII-2, and
FnIII-3). The FnIII-2 domain structure is interrupted by a large
(120 residue) insert domain that contains the furin cleavage
site. Disulfide bonds covalently connect the a- and b-chains as
well as each subunit of the homodimer (interdimer).
Ligand binding induces conformational changes in the extra-
cellular region of IGF-1R that results in the activation of the intra-
cellular tyrosine kinase domains. IGF-1R activation leads to
recruitment and activation of various adaptor proteins that in
turn promote a range of cellular responses, most notably cell
survival and cell-cycle progression. The mitogenic and cell-
survival activities of the IGF-1 and IGF-2 ligands have been
shown to enhance the formation of atherosclerotic plaques as
well as promote tumor growth (Clemmons, 2007; Pollak, 2008).
Based on a wealth of preclinical data, epidemiology, and in
rare cases the identification of direct genetic aberrations linked
to cancer, IGF-1R has emerged as a strongly pursued target in
oncology (Pollak, 2008). Both small molecule and antibody
approaches are being tested in mid- and late-stage clinical trials
for various forms of cancer.
As homodimers, both IR and IGF-1R hypothetically contain
two identical ligand binding sites. However, the IR/IGF-1R
systems are classical models of negative cooperativity. Using
Scatchard analyses, 125I-labeled ligands are competed off their
receptors by unlabeled ligands in a curvilinear fashion with
apparent high affinity and low affinity events (Christoffersen
et al., 1994; De Meyts et al., 1973; Gavin et al., 1973). Addition-
ally, unlabeled ligands induce enhanced dissociation of pre-
bound 125I-ligands from both IR and IGF-1R. This negative
cooperativity requires significant regions of the receptors to be
present, including domains L1, CRR, L2, FnIII-1, and exon 10,
which encodes residues 704–719 of the insert domain (ID)
(Surinya et al., 2002). The data strongly suggest an asymmetric
receptor conformation in the ligand-bound state leading to the
high- and low-affinity binding modes (De Meyts and Whittaker,
2002). However, very little regarding the defined structural
features of the receptor in its active and asymmetric conforma-
tion has been defined since these discoveries in the early 1970s.
Monoclonal antibodies raised against either IR or IGF-1R can
be relatively inert or can lead to enhanced or reduced ligandreserved
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IGF-1R Activation, Inhibition by H/D Exchangebinding, which is directly related to receptor activation (Soos
et al., 1992; Soos et al., 1986). Inhibitory antibodies, which are
under consideration for cancer therapy, can inhibit ligand
binding in numerous ways ranging from purely allosteric inhibi-
tion to purely competitive inhibition (Doern et al., 2009). Two
inhibitory antibodies, BIIB4 and BIIB5, are examples of purely
competitive and purely allosteric inhibitors, respectively (Doern
et al., 2009). BIIB5 (known externally as BIIB022) is currently
being evaluated for its efficacy against various solid tumors in
human clinical trials (Rodon et al., 2008).
New advances in rapid analytical separation procedures and
mass spectrometry instrumentation have recently enabled the
study of various proteins and protein complexes by mass spec-
trometry-based hydrogen/deuterium (H/D) exchange (Wales and
Engen, 2006). The goal of the study described here was to
examine the precise molecular details of the activated and
inhibited states of IGF-1R by monitoring H/D-exchange of the
receptor followed by proteolytic mass mapping of peptidic
regions. As far as we know, the study of IGF-1R along with its
activating and inhibitory modulators represents the largest
protein studied to date by H/D-exchange mass spectrometry.
First, we analyzed the H/D-exchange properties of IGF-1R in
the absence (apo-state) or presence of IGF-1 (i.e., bound state)
to precisely identify conformational changes within the receptor
associated with activation. We chose IGF-1 instead of IGF-2
because IGF-1 has a higher affinity for the receptor and high
serum concentrations of IGF-1 are associated with an increased
risk and severity of cancer (Clemmons, 2007; Pollak, 2008).
Finally, we studied the H/D-exchange properties of IGF-1R in
the presence of the antibody inhibitors BIIB4 and BIIB5 to help
define conformational features of the inactive state of the
receptor and to provide mechanistic details regarding anti-
body-mediated inhibition.
RESULTS
Generation of a Peptide Map for Enzymatically
Deglycosylated hIGF-1R(1–903)
To simplify the peptide map generated by proteolysis and liquid
chromatography/mass spectrometry (LC/MS), hIGF-1R(1-903)
(a recombinant protein consisting of the entire extracellular
region of the human receptor) was enzymatically deglycosylated
by overnight treatment with PNGaseF. The PNGaseF-treated
protein was re-purified using preparative size exclusion chroma-
tography (SEC) (Figure 1A) and maintained its monodisperse
homodimeric structure. SDS-PAGE analysis (Figure 1B) showed
a reduction in the apparent molecular weight for the PNGaseF-
treated material both in the a- and b-chains. Static light scat-
tering indicated a total molecular size decrease of 35 kDa after
enzymatic treatment (data not shown), which is consistent with
the loss of N-linked glycans from hIGF-1R(1–903). The deglyco-
sylated protein was shown to maintain identical binding to both
IGF-1 and the antibody Fab domains of BIIB4 (competitive inhib-
itor) and BIIB5 (allosteric inhibitor) (Figures 1C and 1D). Differen-
tial scanning calorimetry (DSC) analyses indicated only a small
perturbation in the thermal stability of the hIGF-1R(1–903) after
deglycosylation (Figure 1E). These data all suggest that deglyco-
sylation did not have a big impact on the folding/activity of the
protein.Structure 19The characterized peptide map of hIGF-1R(1–903) had near
complete (94%) coverage of the receptor extracellular domain.
After low pH proteolysis followed by LC/MS, 207 peptides
were unambiguously identified. IGF-1R contains 16 putative
N-linked glycosylation sites. Most are predicted to be occupied
based on an analysis of the glycosylation patterns of IR (Adams
et al., 2000). Subsequent to enzymatic treatment, aglycosyl
peptides were identified in the peptide map that encompassed
14 of 16 putative N-linked glycosylation sites (only asparagines
214 and 717were not identified). The inability to identify peptides
containing asparagines 214 and 717 does not provide informa-
tion regarding the glycosylation state of these sites.
H/D-Exchange within hIGF-1R(1–903)
The phenomenon of H/D-exchange has been extensively
reviewed (Englander and Kallenbach, 1983; Wales and Engen,
2006). Briefly, in proteins H/D-exchange occurs at labile
hydrogen atom positions, whereby hydrogen atoms spontane-
ously change places with other hydrogen atoms in the sur-
rounding solvent. Hydrogens at the backbone amide positions
are of particular interest, because variations in their chemical
and physical environment induced by protein structure affect
the rates of exchange over several orders of magnitude (Smith
et al., 1997). Therefore, information concerning the conformation
of a protein (or of differences between proteins) can be extracted
by monitoring the exchange reaction. It should be noted, when
comparing protein regions with very high or very little structural
density (i.e., where exchange occurs extremely slow or fast),
differences in H/D-exchange will likely not be detected and it is
generally presumed that these regions are not involved in any
structural perturbation.
Near complete peptide map coverage of hIGF-1R(1–903)
enabled detailed determination of the H/D-exchange dynamics
of peptides from each domain of the protein (see Table S1 avail-
able online). H/D-exchange was determined by measuring the
centroid of each peptide’s mass envelope and comparing this
value to that determined in the absence of deuterium. The
normalized H/D-exchange behavior of all 207 identified peptides
is graphed in Figure 2. Consistent with the stably folded nature of
the receptor, all peptides on average only exchanged 22% of
their amide protons with solvent after four hours of deuterium
exposure under ambient conditions at neutral pH. By domain,
the CRR region had the highest level of exchange (and the
most rapid, Figure 2), consistent with its relatively absent hydro-
phobic core. Several peptides located in the CRR region reached
amaximum level of exchange at 10 s, which did not change even
after 4 hr of exchange (Figure 2; Table S1). In these areas, H/D-
exchange may occur too quickly to capture any changes in
dynamics. Conversely, the L1 and L2 domains displayed the
highest levels of protection (L1 = 18%, CRR = 34%, L2 = 15%,
FnIII-1 = 27%, FnIII-2 = 23%, ID = 30%, FnIII-3 = 22%). Interest-
ingly, the ID region was significantly protected from solvent, sug-
gesting that it may not be as unstructured as is commonly
believed (Adams et al., 2000).
Ligand-Induced Changes in the H/D-Exchange Behavior
of hIGF-1R(1–903)
The H/D-exchange behavior of hIGF-1R(1–903) was also
monitored in the presence of saturating levels of IGF-1 under, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 891
Figure 1. Purification and Characterization of Deglycosylated hIGF-1R(1–903)
(A) Preparative SEC profile of hIGF-1R(1–903) protein (elution peak at 130 ml) subsequent to overnight treatment with PNGaseF.
(B) SDS-PAGE gel analysis of hIGF-1R(1–903) before and after treatment with PNGaseF. Lanes 1 and 2 are the protein before and after treatment, respectively,
under nonreducing conditions, and lanes 4 and 5 are the protein before and after treatment, respectively, after heat treatment in 200 mM DTT (reducing
conditions).
(C and D) Kinetic SPR binding curves obtained for the binding of IGF-1 at 5 nM (solid green line) and 50 nM (dashed green line), BIIB4 Fab at 3 nM (solid red line)
and 30 nM (dashed red line), andBIIB5 Fab at 3 nM (solid blue line) and 30 nM (dashed blue line) to hIGF-1R(1–903) before (C) and subsequent to (D) treatment with
PNGaseF. The insets have a modified y axis to more clearly show IGF-1 binding.
(E) DSC unfolding curves of hIGF-1R(1–903) before and after treatment with PNGaseF. See also Table S1.
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IGF-1R Activation, Inhibition by H/D Exchangeconditions where 99% of the receptor is expected to be occu-
pied at all times (Doern et al., 2009). Representative plots of
hIGF-1R(1–903) peptides displaying similar and differing H/D-
exchange behavior in the absence and presence of IGF-1 are892 Structure 19, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rightsshown in Figures 3A and 3B, respectively. Differences in the
H/D-exchange behavior of hIGF-1R peptides induced by IGF-1
binding are listed in Table 1 and mapped to the surface of the
crystal structure of the homologous insulin receptor in Figure 4Areserved
Figure 2. H/D Incorporation across hIGF-
1R(1–903)
H/D incorporation across hIGF-1R(1–903) at 10 s
(cyan) and 240 min (black), determined by pH
quenching followed by low temperature and low
pH proteolysis and LC-MS analysis. The plot
shows the relative H/D incorporation of every
detectable hIGF-1R(1–903) peptide from the
N terminus (left) to C terminus (right). The H/D-
exchange data was normalized to a fractional
exchange value by dividing the observed level of
H/D-exchange within each peptide by the total
number of exchangeable residues within that
peptide. For orientation of all hIGF-1R peptides
along the x axis, an arbitrary peptide number was
assigned to each peptide by summing the residue
numbers at the start and end of each peptide and
dividing the value by 2. The lowest value was as-
signed 1, the next lowest value was assigned 2,
and so forth. In this format, the H/D-exchange of
every identified peptide could be shown in a single
plot. The H/D-exchange of all other time points (1,
10, and 60 min) are represented within the region
between the cyan and black traces as the thick-
ness of the black line. The line thickness also
serves as an indicator for the level of backbone dynamics, where continual increases in H/D-exchange over the time course will produce a thick line and low or no
H/D-exchange over the time course will produce a thin line. The schematic diagram below the graph roughly tracks the domain of IGF-1R from which each
peptide was derived. The domain boundaries were defined previously (Adams et al., 2000).
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IGF-1R Activation, Inhibition by H/D Exchange(McKern et al., 2006). Significant changes in H/D-exchange were
not observed in L1, even though this region is known to make
many key contacts with ligand (Whittaker et al., 2001). One
explanation is that many of the amide protons from residues
within the L1 region known to be crucial for IGF-1 binding are
highly protected from solvent in the apo-state and therefore do
not become more protected in the IGF-1-bound state. For
example, hIGF-1R peptides consisting of residues 28–33 and
75–79, which form a large portion of the ligand-binding surface
within the L1 domain (Whittaker et al., 2001) show virtually no
H/D-exchange in the apo-state (Table S1) and thus are not pro-
tected further in the IGF-1-bound state. The analysis does not
provide information regarding changes in solvent exposure or
hydrogen bonding within side chains. Amide protection was
observed in a peptide (localized to residues 239–246 of the
CRR region) within the ligand binding pocket known to be impor-
tant for IGF-1 binding (Whittaker et al., 2001).
The most prominent areas of hIGF-1R(1–903) demonstrating
changes inH/D-exchangebehavioron ligandbindingoccurwithin
the L2 and FnIII-1 domains near the homodimeric interface and
within the ID (McKern et al., 2006). IGF-1-induced changes in
the H/D-exchange behavior of residues near the homodimeric
interface likely reflect a conformational changewithin the receptor
that results in concerted changes in both subunits of the homo-
dimer. Alanine-scanningmutagenesis of residues 692–701within
the ID has demonstrated that this region plays an important role in
IGF-1 binding (Whittaker et al., 2001). Consistent with these
results, we found that this region becomes significantly protected
from H/D-exchange in the presence of ligand (Table 1).
Changes in hIGF-1R(1–903) H/D-Exchange on Binding
of Antibody Inhibitors
BIIB4 and BIIB5 are competitive and allosteric inhibitors of
IGF-1R, respectively (Doern et al., 2009). The BIIB4 epitopeStructure 19was localized to the CRR region and overlaps significantly with
residues known to play a role in ligand binding, whereas the
BIIB5 epitope was localized to the FnIII-1 domain distal to the
ligand binding pocket (Doern et al., 2009). Binding of the BIIB4
and BIIB5 Fabs both induced significant changes in the H/D-
exchange behavior of hIGF-1R(1–903) well beyond their known
epitopes. Peptides whose H/D-exchange rates were modified
by BIIB4 or BIIB5 binding are listed in Table 1 and mapped to
the crystal structure of the insulin receptor (McKern et al.,
2006) in Figures 4B and 4C, respectively.
Consistent with it being a competitive inhibitor of ligand
binding, BIIB4 led to significant protection in both the L1 and
CRR region in areas known to be important for ligand binding
(Table 1 and Figure 4B) (Whittaker et al., 2001). Surprisingly,
many of the BIIB4-induced changes in H/D exchange coincide
with changes induced by IGF-1. However, two peptides were
found (428–448 and 628–648) where IGF-1 led to reduced
H/D-exchange whereas BIIB4 accelerated H/D-exchange.
BIIB5 is an allosteric inhibitor that binds the FnIII-1 domain of
IGF-1R (Doern et al., 2009). The H/D-exchange data agrees well
with what is known regarding BIIB5’s epitope. On binding BIIB5,
a hIGF-1R peptide encompassing residues 465–486, which
contains many of the residues known to impact BIIB5 binding
to the receptor, becomes protected from H/D-exchange (Table
1 and Figure 4C). BIIB5 also induced changes in H/D-exchange
behavior within the IGF-1R homodimeric interface region and
within the ID domain. An area within the ligand-binding pocket
on the L1 domain becomes more labile to exchange (residues
81–86) on BIIB5 binding (Table 1).
Asymmetric H/D-Exchange Patterns within IGF-1R that
Can Be Altered by Agonist/Antagonist Binding
Two hIGF-1R peptides consistently demonstrated peculiar
H/D-exchange profiles that could not be explained by EX1 or, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 893
Figure 3. Time Course of H/D-Exchange within Peptides Derived
from hIGF-1R(1–903)
H/D exchange was measured in the absence (-, dotted line) and presence
(C, solid line) of a saturating level of hIGF-1. The plots show representative
peptides with no difference (A) or a significant difference (B) in exchange
behavior in the presence or absence of IGF-1 based on the centroid of their
mass envelopes. (A) Blue = residues 1–8; green = 204–228; orange = 333–339;
red = 735–740. (B) Blue = residues 428–448; green = 544–551; orange = 628–
649. Residues 204–228 within the CRR region demonstrate significant
exchange (>50% amide exchange) in both the apo- and IGF-1-bound states,
suggesting this region is significantly exposed to solvent. Error bars indicate
the standard error determined over an average of three experiments.
Structure
IGF-1R Activation, Inhibition by H/D Exchangesimple EX2 H/D-exchange mechanisms (428–448 and 628–648)
(Weis et al., 2006b). Shown in Figure 5A is a typical EX2-type shift
in the mass envelope of a peptide (residues 466–489) over time
on exposure to deuterium at neutral pH at ambient temperature
(apo-IGF-1R state). Nearly all the hIGF-1R(1–903) peptides
demonstrated this uniform EX2-type exchange behavior.
However, the mass envelopes of peptides consisting of residues
428–448 (within the L2 domain near the interfacewith FnIII-1) and
628–648 (within FnIII-2 at the junction with the ID) split
into two mass envelopes, one that is largely protected from
H/D-exchange and one that exchanges more rapidly (Figures894 Structure 19, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights5B and 5C). This phenomenon could be distinguished from
EX1-type exchange because both envelopes demonstrated
a shift in the centroid of their mass envelopes relative to the un-
exchanged peptide per unit exchange time, which is consistent
with EX2 exchange. In an EX1 scenario, the unexchanged
mass envelope would be expected to decrease in population
over time, whereas the fully exchanged mass envelope would
be expected to increase proportionally, which does not correlate
with the phenomenon observed here. Continuous injections of
a protein sample have also been shown to cause false EX1-like
exchange profiles, resulting from peptide carryover (Fang
et al., 2011). However, this occurrence was ruled out: each
protein sample was followed by a rigorous washing and two
buffer blank injections, both of which showed no evidence of
peptide carryover. Instead, these peptides seem to exist in two
distinctly different chemical environments, one protected from
exchange and one that exchanges more readily (Figures 5B
and 5C). Some peptides that overlapped in primary sequences
did not demonstrate these two separately exchanging popula-
tions. Therefore, the regions involved in this asymmetric
exchange could be further localized to residues 428–437 and
641–648 of IGF-1R.
Next, the effect of adding an agonist (IGF-1) or antagonists
(inhibitory antibodies) on the populations of the two apparently
distinct chemical states was assessed. Interestingly, in the pres-
ence of IGF-1, the protected state in both the 428–448 and
628–648 peptides increased significantly (Figures 6A and 6B).
Theantibody antagonists, BIIB4andBIIB5, both had largeeffects
on the asymmetric H/D-exchange behavior discovered within
hIGF-1R(1–903). Opposite to what was observed in the presence
of IGF-1, both antibody Fabs eliminated the protected state
within peptide 428–448 (Figure 6B). Within peptide 628–648,
BIIB4, the competitive inhibitor, eliminated the protected state,
whereas BIIB5 led to a slightly higher population of the protected
state similar to what was observed with IGF-1 (Figure 6C).
DISCUSSION
The H/D-exchange data agree well with what is known regarding
the structural features of IGF-1R (Garrett et al., 1998; McKern
et al., 2006) and provide additional information regarding
dynamics and accessibility across the receptor. Unsurprisingly,
the CRR region, which lacks a hydrophobic core, exchanges
the most extensively and most rapidly compared with other
domains of IGF-1R (Figure 2). However, the relatively slow H/D-
exchange behavior within the ID (similar to the H/D-exchange
observed for the FnIII domains as a whole) was unanticipated
(Figure 2). The ID is known to be mobile and make long-range
contacts with the N-terminal L1 domain of the receptor in the
ligand-bound state (Ward et al., 2008). The ID is often depicted
as a relatively unstructured or loosely organized polypeptide
whose interactions with other regions of the receptor are modi-
fied by IGF binding. The data here suggest that the ID domain,
although mobile, is organized in some fashion that precludes
rapid and extensive H/D-exchange.
The binding of IGF-1 led to both expected and unexpected
changes in H/D-exchange patterns within the receptor. Cor-
relating well with what is known regarding the ligand-binding
pocket (Whittaker et al., 2001), residues within the CRRreserved
Table 1. Changes in hIGF-1R(1–903) H/D-Exchange in the Absence or Presence of IGF-1 or Inhibitory Antibodies
IGF-1R Peptide
IR Structure
Residue No. (2dtg)
H/D-Level
Apo – Bound
(1 min)
H/D-Level
Apo – Bound
(10 min)
H/D-Level
Apo – Bound
(60 min)
H/D-Level
Apo – Bound
(240 min)
IGF-1
138–156 144–163 0.4 0.0 0.4 0.9
239–261a 246–253 0.7 0.3 0.6 0.0
298–315 308–325 0.5 0.3 0.5 0.0
327–356 337–366 0.6 0.6 0.7 0.1
428–448a,b 438–458 0.6 0.9 1.3 1.3
480–489 490–499 0.7 0.5 0.6 0.2
544–551 559–566 0.7 0.8 0.3 0.2
572–579 586–593 0.2 0.7 0.3 0.1
628–648a,b 642–662 0.8 1.1 1.3 1.6
696–701 xxxxxx 0.7 0.2 0.1 0.0
BIIB4
33–47 37–53 0.5 0.5 0.7 0.7
87–109a 93–115 1.8 1.4 0.8 2.1
172–196 179–203 0.7 0.3 0.4 0.3
229–248 236–255 0.3 0.8 0.7 1.0
284–312 295–322 0.1 0.1 1.3 0.7
323–341 333–351 0.2 0.4 0.3 0.3
331–349 341–359 0.1 1.0 1.3 1.2
428–448b 438–458 -2.2 -3.3 -2.8 -3.1
451–474 461–485 2.0 1.8 1.2 1.0
463–475 474–486 0.1 0.4 0.4 0.4
524–550 534–565 0.1 0.6 0.5 0.7
555–569 569–583 1.0 0.0 0.3 0.4
556–571 570–585 0.1 0.2 0.3 0.6
628–648b 642–662 0.8 1.4 1.9 1.1
783–812 793–822 0.6 0.9 0.1 0.3
BIIB5
81–86 87–92 0.0 0.9 0.7 0.7
428–448b 438–458 — 2.3 1.7 1.9
465–486 476–497 0.4 0.4 0.5 0.5
558–571 572–585 0.8 0.8 1.2 1.2
628–648b 642–662 1.2 0.7 1.0 1.2
719–732 xxxxxx 1.3 0.9 0.7 0.9
819–832 829–842 0.0 0.1 0.2 0.2
IR, insulin receptor.
aChanges in H/D-exchange on IGF-1 or BIIB4 binding can be localized to smaller regions based on data from overlapping peptides (i.e., 239–246,
428–437, and 641–648, respectively, for IGF-1 and 87–92 for BIIB4).
b Peptide demonstrates two separate H/D-exchange patterns. Changes in H/D incorporation are based on the average mass of the two mass
envelopes.
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IGF-1R Activation, Inhibition by H/D Exchange(239–244), L2 (323–349, 451–474), and ID (696–701) that either
face the ligand-binding pocket or have been shown to be impor-
tant for ligand binding undergo protection from H/D-exchange in
the presence of IGF-1. Interestingly, IGF-1R residues 696–701
are adjacent to residues 688-695 (residues 701–708 of IR), which
have been shown recently to be part of a helical segment of the
ID within IR called the aCT that packs against the L1 domain and
completes the ligand binding site of the receptor (Smith et al.,
2010). Based on alanine-scanning mutagenesis of IGF-1R,Structure 19Whittaker et al. (2001) have demonstrated the critical nature of
IGF-1R residue F701 and to a lesser extent residues 696, 697,
698, and 700 for maintaining a strong interaction with IGF-1.
Thus, the interaction of residues 688–695 of the aCT peptide of
IGF-1R (701–708 of IR) appear to pin the helical aCT segment
against the L1 domain (Smith et al., 2010), whereas residues
696–701 (709–714 of IR) likely make strong direct contacts
with ligand based on the H/D-exchange protection afforded
by the addition of ligand. IGF-1 binding also led to changes in, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 895
Figure 4. Ligand- and Antibody-Induced
Changes in the H/D-Exchange Behavior of
hIGF-1R(1–903)
Changes in H/D-exchange in absence and pres-
ence of IGF-1 (A), BIIB4 (B), BIIB5 (C) were map-
ped to the surface of the crystal structure of the
insulin receptor (PDB code 2DTG) (McKern et al.,
2006). Red indicates protection from exchange
(less exchange), and blue indicates increased
exchange on the binding of IGF-1, BIIB4 Fab, or
BIIB5 Fab. The bottom IR structure orientation
shows the IGF-1-, BIIB4-, and BIIB5-induced
changes in H/D-exchange in the interface region
of IGF-1R/IR (L2 and FnIII-1). The figure is anno-
tated to highlight the ligand-binding pocket (A),
the epitopes of BIIB4 (B), and BIIB5 (C), and the
two regions of IGF-1R that demonstrated asym-
metric H/D exchange.
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IGF-1R Activation, Inhibition by H/D ExchangeH/D-exchange patterns at the homodimeric interface, suggest-
ing that ligand binding modifies the arrangement of the two
subunits of the receptor homodimer.
The inhibitory antibodies, BIIB4 and BIIB5, both led to signifi-
cant changes in H/D-exchange patterns across the entire
hIGF-1R extracellular region. BIIB5 is known to be an allosteric
inhibitor (Doern et al., 2009); however, exactly how it modifies
the affinity of the IGFs for IGF-1R was unclear. BIIB5 has previ-
ously been shown to reduce the rate of IGF-1 binding to
IGF-1R (Doern et al., 2009). Based on the H/D-exchange data,
it seems possible that BIIB5 lowers the ligand affinity for the
receptor by disorganizing the ligand-binding site and forcing
the ligand to provide an additional ‘‘organizing step’’ in the
process of its binding. This hypothesis agrees with the reduced
rate of binding between the receptor and its ligands in the pres-
ence of BIIB5. BIIB4 had a more profound effect on the
H/D-exchange patterns of IGF-1R. Binding of BIIB4 clearly led
to a strong protective effect on the CRR and flanking L1 and
L2 domains—apparently locking the structure down. This corre-
lates well with its known epitope. It also correlates with circular
dichroism (CD) data demonstrating a big increase in b sheet
propensity on BIIB4 binding, as well as calorimetry data indi-896 Structure 19, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights reservedcating that BIIB4 has a heat capacity of
binding (CP = 1000 cal mol1 oC1)
that is much higher than would be ex-
pected based on a typical antibody-
binding surface (Doern et al., 2009;Geier-
haas et al., 2007). Thus, BIIB4 appears to
induce strong local and long-range struc-
tural changes across the receptor. BIIB4
binding to IGF-1R leads to very distinct
changes in the H/D-exchange behavior
of the receptor compared with the
changes observed with BIIB5. Perhaps
this is one reason why the combination
of the inhibitory antibodies has such a
profound inhibitory affect on the receptor
(Dong et al., 2010, 2011). The concerted
changes the inhibitors make in the recep-
tor move it further from the activatedstate induced by IGF-1. CD spectra of a ternary complex of the
BIIB4 and BIIB5 Fabs and hIGF-1R(1–903) appear to contain
the combination of hIGF-1R(1–903) structural changes induced
by each antibody in isolation (Dong et al., 2010). This antibody
combination was significantly more effective at reducing IGF-1R
signaling and IGF-1R-induced tumor growth in both in vitro
and in vivo settings (Dong et al., 2010). Recently, a bispecific
antibody has been reported that contains both the BIIB4 and
BIIB5 reactivitieswith the goal of having improved efficacy in clin-
ical trials over monospecific anti-IGF-1R antibodies that are
currently under clinical evaluation (Doern et al., 2009; Pollak,
2008).
Perhaps the most interesting discovery with regards to the
H/D-exchange behavior of IGF-1R was the existence of two
asymmetrically exchanging populations within the receptor.
Asymmetry is known to be an important facet of the signaling
of both the IR and epidermal-like growth factor receptor
(EGFR) families. Only recently have many of the structural
features behind the asymmetric signaling within the EGFR family
been elucidated (Alvarado et al., 2010; Zhang et al., 2006).
While asymmetry has been associated with IR/IGF-1R ligand
binding for nearly forty years (Christoffersen et al., 1994;
Figure 5. Mass Envelopes at Increasing Time Points for Peptides
Demonstrating Both Typical and Asymmetric H/D Exchange
Shown are the peptide mass envelopes (top to bottom) of peptides 466–489
(A), 428–448 (B), and 628–648 (C). Peptide 466–489 (A) is a highly represen-
tative H/D-exchange profile showing an overall shift in themass envelope upon
H/D incorporation. Peptides 428–448 (B) and 628–648 (C) were found to have
asymmetric H/D-exchange patterns, where two populations of each peptide
appear to exchange at different rates—suggesting that each peptide exists in
two separate chemical environments. The shifting of the centroid of both
isotopic populations indicates this phenomenon is not EX1-exchange
behavior.
Figure 6. Ligand- and Antibody-InducedChanges in the Asymmetric
H/D-Exchange Populations of Peptides 428–448 and 628–648
Shown are the mass envelopes of peptides 428–448 (A) and 628–648 (B) of
hIGF-1R(1–903) after 240min of H/D exchange in the absence and presence of
IGF-1 or the inhibitory antibodies.
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Structure 19De Meyts et al., 1973), little regarding defined structural aspects
of the asymmetric state of the receptors has been elucidated—
even though global conformational studies have been described
recently (Whitten et al., 2009). We found two regions of hIGF-1R
(residues 428–448 in L2 near the homodimeric interface and resi-
dues 628–648 adjacent to the ID) that demonstrated two distinct
H/D-exchange populations in apo-hIGF-1R(1–903) (Figures 5A
and 5B). There is no formal way of ruling out that this asymmetry
is associated with two separate conformations of the receptor in
two separate molecules (i.e., not within the same homodimer).
However, because IGF-1R displays strong negative cooperativ-
ity when binding ligand (Christoffersen et al., 1994; De Meyts
et al., 1973) and the protected population of both peptides is
always fractional in the presence of ligand (Figures 6A and 6B),
it seems likely the two states represent an asymmetric environ-
ment within each homodimericmolecule that is favored on ligand
binding. Asymmetry within each of the homodimeric subunits
(i.e., each L1-CRR-L2-FnIII-1-FnIII-2-FnIII-3 half of the receptor)
might be expected if each subunit were to adopt distinct, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 897
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interface, and residues 628–648 are adjacent to residues
669–672 that are involved in interdimer disulfide-bond formation
(Adams et al., 2000). The adoption of distinct conformations
within each homodimeric subunit near these interfacial regions
may play a role in both of these peptides inhabiting two distinct
chemical environments.
In the 628–648 peptide in particular, the population that
exchanged more slowly, dubbed the protected state, was
present in apo-IGF-1R at a much lower population than the
more rapidly exchanging state. If the asymmetric state repre-
sents the active conformation of the receptor, then this protected
state population may reflect a low level of constitutive activity,
even in the absence of ligand. Indeed, we have observed that
the full-length receptor demonstrates a low level of autophos-
phorylation even in the apo-state (S.J.D., E. Langley, and J.
Dong, unpublished data). This may be another indication that
the population of the protected state of the 628–648 peptide
provides a measure of the active population of IGF-1R. Why
the population of the protected state within residues 428–448
(in apo-IGF-1R) differed from what was observed for residues
628–648 remains a mystery.
All three activity modifying agents (IGF-1, BIIB4, and BIIB5)
induced significant changes in the H/D-exchange behavior of
the two peptides, 428–448 and 628–648, which exist in two
distinct chemical environments, away from the H/D-exchange
observed within apo-hIGF-1R. Saturation of the receptor with
IGF-1 led to a significant increase in the population of the pro-
tected state of each of these peptides. The competitive inhibitor,
BIIB4, entirely eliminated the protected states of both peptides,
potentially forcing the receptor into a completely symmetrical
and inactive state. The allosteric inhibitor, BIIB5, led to a complex
modification of these asymmetric peptides, eliminating the
protected state within residues 428–448, while enhancing the
protected state within residues 628–648. Surinya et al. (2002)
describe the inhibitory activities of an anti-IR antibody (47–9)
with a similar epitope as BIIB5. Like insulin, the 47-9 antibody
could accelerate 125I-insulin dissociation from the receptor—a
hallmarkofnegativecooperativity. Theantibodycouldonly induce
accelerated 125I-insuiln release if residues 650–704 (636–690 of
IGF-1R) were included in the soluble IR extracellular domain
construct. This region overlaps with residues 641–648 where we
demonstrate the asymmetry to originate from andwhose popula-
tion of the protected state is enhanced by both IGF-1 and BIIB5
(even though BIIB5 can clearly occupy both its receptor epitopes
simultaneously (Doern et al., 2009) and eliminates the protected
state of residues 428–448). Thus, there is some precedence for
residues 636–690 being involved in negative cooperativity.
Although the data with the allosteric inhibitor is ambiguous in
terms of its effect on receptor symmetry, it is clear that ligand
binding enhances receptor asymmetry whereas the competitive
inhibitor appears to trap the receptor in a symmetric environment.
The populations of the ‘‘protected states’’ of these two peptides
thus appear to serve as nonposttranslational modification
reporters of the active/inactive states of IGF-1R. The ability to
quantify the asymmetry may be useful for the design of biologic
therapeutics targeting the receptor or ultimately as markers in
a translational medicine setting that quantify IGF-1R activity in
tumor patients and whether they respond to anti-IGF-1R therapy.898 Structure 19, 890–900, June 8, 2011 ª2011 Elsevier Ltd All rightsEXPERIMENTAL PROCEDURES
hIGF-1R(1–903), IGF-1, BIIB4 Fab, and BIIB5 Fab
The hIGF-1R(1–903) protein with a C-terminal 10 histidine tag was produced in
chinese hamster ovary (CHO) cells and purified as described previously (Doern
et al., 2009). Human IGF-1 was fromR&D Systems. BIIB4 and BIIB5 Fabs were
produced as described previously (Doern et al., 2009).
Deglycosylation of hIGF-1R(1–903)
The hIGF-1R(1–903) protein (4 mg at 1.5 mg/ml) was dialyzed into 20 mM Tris,
pH 8.0. The N-glycanase PNGaseF (Prozyme) was added (2 units), and the
mixture was incubated overnight at room temperature. The deglycosylated
protein was purified from PNGaseF and detached glycan using a preparative
Superdex200 SEC column linked to an AKTA Explorer (GE Healthcare). The
SEC column was pre-equilibrated in phosphate buffered saline (PBS).
Characterization of Deglycosylated hIGF-1R(1–903)
Deglycosylated hIGF-1R(1–903) protein was compared with untreated hIGF-
1R(1–903) by SDS-PAGE, differential scanning calorimetry (DSC), analytical
SEC with in-line static light scattering, and surface plasmon resonance
(SPR). For SDS-PAGE analysis, 5 mg nonreduced and 10 mg reduced samples
(heated in 200 mMDTT) were applied to 4%–12%NuPAGE Bis-Tris gels using
the buffers and protocols of the manufacturer (Life Technologies).
DSC scans were performed using an automated capillary DSC (capDSC, GE
Healthcare). PNGase treated and untreated hIGF-1R(1–903) protein solutions
and reference (buffer) solutions were sampled automatically from a 96-well
plate using the robotic attachment. Before each protein scan, two buffer scans
were performed to define the baseline for subtraction. All 96-well plates con-
taining protein were stored within the instrument at 6C. Each sample was run
at 0.5 mg/ml in PBS. Scans were performed from 10C–95C at 2C/min using
the low feedback mode. Scans were analyzed using the Origin software
supplied by the manufacturer. Subsequent to the subtraction of reference
baseline scans, nonzero protein scan baselines were corrected using
a third-order polynomial.
For quantitative molecular size determination, 30 mg of deglycosylated and
untreated hIGF-1R(1–903) were individually injected onto a Phenomenex
BioSep-SEC-s3000 7.8 mm 3 30 cm analytical SEC column equilibrated in
10 mM phosphate, 150 mM NaCl, 0.02% NaN3 at pH 6.8 using an Agilent
1100 HPLC system. Light scattering data for material eluting from the SEC
column were collected using a miniDAWN static light scattering detector
coupled to an in-line refractive index meter (Wyatt Technologies). Ultraviolet
data were analyzed using HPCHEM (Agilent), and light scattering data were
analyzed using ASTRA V (Wyatt).
All SPR experiments were performed on a Biacore 3000 set to 25C using
HBS-EP running buffer (GE Healthcare). An anti-HisTag antibody (PENTA-His,
QIAGEN) was immobilized to 10,000 resonance units (RUs) on a CM5 chip
surface at 20 mg/ml in 10 mM acetate, pH 4.0 using the standard amine
chemistry protocols provided by themanufacturer. hIGF-1R(1–903) (untreated
or treated with PNGaseF) was captured on the PENTA-His surface by injecting
20 ml of 40 nM protein at 2 ml/min. On capture of either treated or untreated
hIGF-1R(1–903), 160 ml injections of 30 nM and 3 nM solutions of BIIB4 or
BIIB5 Fabs were injected at 20 ml/min followed by a 30 min dissociation period
with a constant flow of HBS-EP buffer. Alternately, 50 nM and 5 nM solutions of
IGF-1were injected in place of the Fabs. Each injection series was regenerated
using 23 10 ml injections of 0.1M glycine, pH 2.0, at 60 ml/min. Each curve was
double referenced using (1) data obtained from a blocked surface devoid of the
PENTA-His antibody; and (2) data from a primary injection of hIGF-1R(1–903),
followed by a secondary injection of HBS-EP buffer.
H/D-Exchange Mass Spectrometry
H/D-exchange was performed as previously described (Houde et al., 2009).
The time course for labeling was 10 s, 1 min, 10 min, 60 min, and 240 min.
Deuterium labeling was quenched by reducing the pH to 2.5–2.6 and lowering
the temperature to 0C. Quenched samples were digested online with pepsin,
desalted, and separated using a special Waters UPLC system designed for
H/D-exchange (Wales et al., 2008). A 9-min linear acetonitrile gradient
(2%–40%) was used to separate the peptides; both mobile phases contained
0.05% formic acid. Eluate from the C18 column was directed into a Watersreserved
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IGF-1R Activation, Inhibition by H/D ExchangeQTof Synapt HD mass spectrometer with electrospray ionization and lock-
mass correction (using Glu-fibrinogen peptide). Mass spectra were acquired
from m/z 255 to 1800. Pepsin fragments were identified using replicate injec-
tions and a combination of exact mass and MSE, aided by Waters IdentityE
software (Silva et al., 2006). Peptide deuterium levels were determined using
the Excel-based program HX-Express (Weis et al., 2006a) and other custom
macros. No adjustment was made for deuterium back-exchange during the
analysis; therefore, all results are reported as relative deuterium level (Wales
and Engen, 2006). Approximately 94% of the hIGF-1R amino acid sequence
was covered by the peptic fragments in these experiments, which constituted
over 200 identified peptides (Table S1). Each analysis was repeated two to four
times over the course of several months, and each protein injection was fol-
lowed with column washing and two buffer blank injections. Based on our
observations using repeat injections, we found that the error associated with
deuterium level determination was 0.1–0.3 Da (that is, ±0.05–0.15 Da for
each data point), similar to that reported elsewhere (Burkitt and O’Connor,
2008).
Determination of Saturating Ligand/Fab Conditions for
H/D-Exchange Mass Spectrometry Binding Experiments
Conditions were derived where hIGF-1R(1–903) would beR98% in the IGF-1-,
BIIB4 Fab-, or BIIB5 Fab-bound state (Engen, 1999; Sancho et al., 1991).
For two interacting proteins, the equilibrium dissociation constant, KD, is
described as
P+ L5PL;KD =
PFLF
PLB
;PF =PT  PLB; LF = LT  PLB; (1)
where P is hIGF-1R(1–903), L is IGF-1, BIIB4, or BIIB5, PL is the complex
between hIGF-1R(1–903) and any of the ligands, PF and LF are the concentra-
tions of hIGF-1R(1–903) and ligand, respectively, unbound in solution, PT and
LT are the total concentrations of each component in solution, and PLB is the
concentration of the binary complex of ligand and receptor. Substituting for
PF and LF leads to the following:
ðPT  PLBÞðLT  PLBÞ
PLB
=KD: (2)
Equation 2 can be rearranged into a quadratic equation to solve for PLB:
PLB =
ðKD +PT + LT Þ±
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðKD +PT + LT Þ2 + 4ðPT ÞðLT Þ
q
2
: (3)
PF and LF can then be determined from Equation 1 enabling the percentages
of free versus bound protein to be estimated. The affinities of IGF-1, BIIB4, and
BIIB5 for hIGF-1R(1–903) have been determined to be 20 nM, 4 nM, and
1.5 nM, respectively (Doern et al., 2009). To analyze the H/D-exchange
behavior of hIGF-1R(1–903) in the IGF1-bound state, the labeling solution
consisted of 250 nM hIGF-1R(1–903) (based on its monomeric molecular
weight of 105 kDa) and 1.6 mM IGF-1. Under these conditions, the receptor
was expected to be 98.5% in the IGF-1-bound state at equilibrium. To analyze
the H/D-exchange behavior of hIGF-1R(1–903) in the presence of the antibody
inhibitors, the labeling solutions consisted of 300 nM hIGF-1R(1–903) and
460 nM BIIB4 Fab or 600 nM BIIB5 Fab where the receptor was expected to
be 97.7% and 98.5% in the Fab-bound states, respectively.
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